Argus initiated coverage of Edwards Lifesciences (EW) with a Buy rating and $90 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences’ SAPIEN X4 Valve Study: A Potential Game-Changer in Heart Valve Treatment
- Edwards Lifesciences’ PASCAL System: A Promising Solution for Tricuspid Regurgitation
- Edwards Lifesciences’ Pivotal Trial: A Game Changer in Tricuspid Valve Repair?
- Edwards Lifesciences’ PROGRESS Trial: A Game Changer for Aortic Stenosis Treatment?
- Edwards Lifesciences’ PASCAL System Trial: A Potential Game-Changer for Tricuspid Valve Repair